pmid	doi	title	Hugo_Symbol
36051080	10.1002/jha2.535	Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphoma.	MTOR
36029491	10.14715/cmb/2022.68.5.21	Effects of Atractylon on Proliferation and Apoptosis of Intestinal Cancer Cells Through PI3K/AKT/mTOR Signaling Pathway.	MTOR
35981361	10.19746/j.cnki.issn.1009-2137.2022.04.012	[Effect of Netrin-1 on VEGFA Expression in T-ALL Cells and Its Related Mechanism].	MTOR
35929918	10.1080/01443615.2022.2106834	The effects of REG4 expression on chemoresistance of ovarian cancer.	MTOR
35908982	10.1016/j.blre.2022.100992	Follicular lymphoma: The long and winding road leading to your cure?	MTOR
35875136	10.3389/fonc.2022.913487	Phosphoproteomic Analysis Reveals a Different Proteomic Profile in Pediatric Patients With T-Cell Lymphoblastic Lymphoma or T-Cell Acute Lymphoblastic Leukemia.	MTOR
35864538	10.1186/s13045-022-01315-2	hUC-EVs-ATO reduce the severity of acute GVHD by resetting inflammatory macrophages toward the M2 phenotype.	MTOR
35857791	10.1080/15548627.2022.2100105	Lack of COL6/collagen VI causes megakaryocyte dysfunction by impairing autophagy and inducing apoptosis.	MTOR
35810594	10.1016/j.bbrc.2022.06.089	RHEB is a potential therapeutic target in T cell acute lymphoblastic leukemia.	MTOR
35785030	10.1155/2022/2253436	Targeting Inhibition of Accumulation and Function of Myeloid-Derived Suppressor Cells by Artemisinin via PI3K/AKT, mTOR, and MAPK Pathways Enhances Anti-PD-L1 Immunotherapy in Melanoma and Liver Tumors.	MTOR
35774848	10.1155/2022/3276925	Identification of CXCR4 Upregulation in Diffuse Large B-Cell Lymphoma Associated with Prognostic Significance and Clinicopathological Characteristics.	MTOR
35774599	10.3389/fphar.2022.914733	UPLC-MS/MS Technology for the Quantitative Methodology and Pharmacokinetic Analysis of Voxtalisib in Rat Plasma.	MTOR
35757978	10.1002/jbt.23117	l-Asparaginase synergizes with etoposide via the PI3K/Akt/mTOR pathway in Epstein-Barr virus-positive Burkitt lymphoma.	MTOR
35743211	10.3390/ijms23126773	Mechanisms of Sensitivity and Resistance of Primary Effusion Lymphoma to Dimethyl Fumarate (DMF).	MTOR
35740513	10.3390/cancers14122847	Combined High-Throughput Approaches Reveal the Signals Driven by Skin and Blood Environments and Define the Tumor Heterogeneity in Sézary Syndrome.	MTOR
35730922	10.1080/10428194.2022.2086247	SPAG5 as a novel biomarker and potential therapeutic target via regulating AKT pathway in multiple myeloma.	MTOR
35713434	10.1097/MD.0000000000029312	KIF23 is a potential biomarker of diffuse large B cell lymphoma: Analysis based on bioinformatics and immunohistochemistry.	MTOR
35688904	10.1007/s00277-022-04876-x	Adverse events in lymphoma patients treated with phosphoinositide 3 kinase Inhibitor in clinical trials: a meta-analysis.	MTOR
35674939	10.1007/s12032-022-01707-x	Pentacyclic triterpenoid ursolic acid induces apoptosis with mitochondrial dysfunction in adult T-cell leukemia MT-4 cells to promote surrounding cell growth.	MTOR
35671182	10.1097/CM9.0000000000001916	Hepatocyte growth factor protects pulmonary endothelial barrier against oxidative stress and mitochondria-dependent apoptosis.	MTOR
35640776	10.1016/j.lfs.2022.120675	Selenium nanoparticles overcomes sorafenib resistance in thioacetamide induced hepatocellular carcinoma in rats by modulation of mTOR, NF-κB pathways and LncRNA-AF085935/GPC3 axis.	MTOR
35626685	10.3390/cells11101648	SMER28 Attenuates PI3K/mTOR Signaling by Direct Inhibition of PI3K p110 Delta.	MTOR
35625998	10.3390/cancers14102392	Novel T Follicular Helper-like T-Cell Lymphoma Therapies: From Preclinical Evaluation to Clinical Reality.	MTOR
35614940	10.3389/fphar.2022.875372	Recent Advances in Dual PI3K/mTOR Inhibitors for Tumour Treatment.	MTOR
35571080	10.3389/fphar.2022.875016	Anticancer Activities of <i>Polygonum odoratum</i> Lour.: A Systematic Review.	MTOR
35558005	10.1177/17588359221093745	Novel insights into the biomarkers and therapies for primary central nervous system lymphoma.	MTOR
35517800	10.3389/fphar.2022.875330	Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives.	MTOR
35510955	10.15252/emmm.202215816	A preclinical model of peripheral T-cell lymphoma GATA3 reveals DNA damage response pathway vulnerability.	MTOR
35483878	10.1101/mcs.a006188	The utility of cerebrospinal fluid-derived cell-free DNA in molecular diagnostics for the <i>PIK3CA</i>-related megalencephaly-capillary malformation (MCAP) syndrome: a case report.	MTOR
35467473	10.1080/17474086.2022.2061455	Advances in therapeutic strategies for primary CNS B-cell lymphomas.	MTOR
35397422	10.1016/j.bbrc.2022.03.105	Poricoic acid A (PAA) inhibits T-cell acute lymphoblastic leukemia through inducing autophagic cell death and ferroptosis.	MTOR
35381283	10.1016/j.ijbiomac.2022.03.212	Molecular characterization, expression and anti-tumor function analysis of yak IFITM2 gene.	MTOR
35336821	10.3390/biology11030449	Post-Irradiation Thymic Regeneration in B6C3F1 Mice Is Age Dependent and Modulated by Activation of the PI3K-AKT-mTOR Pathway.	MTOR
35321703	10.1186/s12906-022-03568-3	Polyphenols in Ilex latifolia Thunb. inhibit human lung cancer cell line A549 by regulation of the PI3K-Akt signaling pathway.	MTOR
35306048	10.1016/j.exphem.2022.03.005	CRLF2 overexpression results in reduced B-cell differentiation and upregulated E2F signaling in the Dp16 mouse model of Down syndrome.	MTOR
35304656	10.1007/s10565-022-09708-2	Chemokine (C-X-C motif) ligand 1 maintains the immune surveillance function of natural killer cells via the PDK2/mTOR signaling pathway.	MTOR
35291908	10.1080/21655979.2022.2042142	Protective effect of phillyrin against cerebral ischemia/reperfusion injury in rats and oxidative stress-induced cell apoptosis and autophagy in neurons.	MTOR
35259456	10.1016/j.cellsig.2022.110301	Investigation of the function of the PI3-Kinase / AKT signaling pathway for leukemogenesis and therapy of acute childhood lymphoblastic leukemia (ALL).	MTOR
35257981	10.1016/j.drup.2022.100822	Targeting metabolism to overcome cancer drug resistance: A promising therapeutic strategy for diffuse large B cell lymphoma.	MTOR
35248829	10.1016/j.redox.2022.102268	mTOR inhibition downregulates glucose-6-phosphate dehydrogenase and induces ROS-dependent death in T-cell acute lymphoblastic leukemia cells.	MTOR
35237397	10.1177/20406207221080743	Mantle cell lymphoma management trends and novel agents: where are we going?	MTOR
35220934	10.2174/1568009622666220225121009	ND-16: A Novel Compound for Inhibiting the Growth of Cutaneous T Cell Lymphoma by Targeting JAK2.	MTOR
35219693	10.1016/j.exer.2022.109004	Casein kinase I inhibitor D4476 influences autophagy and apoptosis in chloroquine-induced adult retinal pigment epithelial-19 cells.	MTOR
35191952	10.1158/1541-7786.MCR-21-0729	PARK2 regulates eIF4B-driven lymphomagenesis.	MTOR
35188042	10.1080/10428194.2022.2042689	Enhanced cytotoxicity of bisantrene when combined with venetoclax, panobinostat, decitabine and olaparib in acute myeloid leukemia cells.	MTOR
35184749	10.1186/s12885-022-09275-z	The PI3K/AKT/mTOR signaling pathway is aberrantly activated in primary central nervous system lymphoma and correlated with a poor prognosis.	MTOR
35174346	10.5187/jast.2021.e128	Effect of hyperthermia on cell viability, amino acid transfer, and milk protein synthesis in bovine mammary epithelial cells.	MTOR
35163615	10.3390/ijms23031693	Predominant Role of mTOR Signaling in Skin Diseases with Therapeutic Potential.	MTOR
35156211	10.1111/jfbc.14111	Evaluation of the protective effects of morin against acrylamide-induced lung toxicity by biomarkers of oxidative stress, inflammation, apoptosis, and autophagy.	MTOR
35105670	10.1158/1541-7786.MCR-21-0729	PARK2 regulates eIF4B-driven lymphomagenesis.	MTOR
35091949	10.1007/s11356-022-18863-2	Cadmium induces apoptosis and autophagy in swine small intestine by downregulating the PI3K/Akt pathway.	MTOR
35091546	10.1038/s41420-022-00833-9	Pharmacological targeting PIKfyve and tubulin as an effective treatment strategy for double-hit lymphoma.	MTOR
35068379	10.1080/16078454.2021.2019363	Application of new targeted drugs in relapsed/refractory primary central nervous system lymphoma.	MTOR
35064010	10.1136/jitc-2021-003766	JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy.	MTOR
35058488	10.1038/s41598-022-04916-6	Inhibition of MCL1 induces apoptosis in anaplastic large cell lymphoma and in primary effusion lymphoma.	MTOR
35053972	10.3390/foods11020240	Protective Effect of <i>Ganoderma atrum</i> Polysaccharide on Acrolein-Induced Apoptosis and Autophagic Flux in IEC-6 Cells.	MTOR
35045655	10.3760/cma.j.issn.0253-2727.2021.11.008	[Effects of L-asparaginase on proliferation, cell cycle and apoptosis of Burkitt lymphoma cell lines].	MTOR
35038545	10.1016/j.exphem.2022.01.004	hnRNPK/Beclin1 signaling regulates autophagy to promote imatinib resistance in Philadelphia chromosome-positive acute lymphoblastic leukemia cells.	MTOR
35035775	10.18632/oncotarget.28177	GZ17-6.02 and palbociclib interact to kill ER+ breast cancer cells.	MTOR
35033818	10.1016/j.bioorg.2022.105607	Anti-leukemic effect and molecular mechanism of 11-methoxytabersonine from Melodinus cochinchinensis via network pharmacology, ROS-mediated mitochondrial dysfunction and PI3K/Akt signaling pathway.	MTOR
35031886	10.1186/s43556-021-00066-9	Combinatorial inhibition of BTK, PI3K-AKT and BRD4-MYC as a strategy for treatment of mantle cell lymphoma.	MTOR
35019715	10.1128/jvi.01941-21	Epstein-Barr Virus LMP1-Activated mTORC1 and mTORC2 Coordinately Promote Nasopharyngeal Cancer Stem Cell Properties.	MTOR
34913612	10.1002/cam4.4466	miR-155-regulated mTOR and Toll-like receptor 5 in gastric diffuse large B-cell lymphoma.	MTOR
34907175	10.1038/s41467-021-27197-5	Interleukin-7 receptor α mutational activation can initiate precursor B-cell acute lymphoblastic leukemia.	MTOR
34900714	10.3389/fonc.2021.766298	Zotatifin, an eIF4A-Selective Inhibitor, Blocks Tumor Growth in Receptor Tyrosine Kinase Driven Tumors.	MTOR
34893112	10.19746/j.cnki.issn.1009-2137.2021.06.017	[Inhibition Effect of Eriodictyol to Growth of DG-75 Cells and the Related Action Mechanism].	MTOR
34877904	10.1080/10428194.2021.2008382	Inhibition of pyrimidine biosynthesis by strobilurin derivatives induces differentiation of acute myeloid leukemia cells.	MTOR
34859142	10.1080/23723556.2021.1979370	From mouse genetics to targeting the Rag GTPase pathway.	MTOR
34836490	10.1080/15548627.2021.1997053	HYPK coordinates degradation of polyneddylated proteins by autophagy.	MTOR
34796518	10.1002/hon.2948	Downregulation of FAPP2 gene induces cell autophagy and inhibits PI3K/AKT/mTOR pathway in T-cell acute lymphoblastic leukemia.	MTOR
34796352	10.5187/jast.2021.e93	Enhanced supply of methionine regulates protein synthesis in bovine mammary epithelial cells under hyperthermia condition.	MTOR
34791836	10.1002/cam4.4422	Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial.	MTOR
34750354	10.1038/s41419-021-04353-9	Cooperative miRNA-dependent PTEN regulation drives resistance to BTK inhibition in B-cell lymphoid malignancies.	MTOR
34745769	10.1080/2162402X.2021.1995999	Metformin promotes anticancer activity of NK cells in a p38 MAPK dependent manner.	MTOR
34737376	10.1038/s41598-021-00950-y	Targeting eIF4F translation complex sensitizes B-ALL cells to tyrosine kinase inhibition.	MTOR
34736967	10.1016/j.ejphar.2021.174612	Selective therapeutic benefit of X-rays and inhibitors of EGFR, PI3K/mTOR, and Bcl-2 in breast, lung, and cervical cancer cells.	MTOR
34729938	10.1111/1759-7714.14184	Hexokinases II-mediated glycolysis governs susceptibility to crizotinib in ALK-positive non-small cell lung cancer.	MTOR
34714908	10.1182/bloodadvances.2021005486	Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways.	MTOR
34710755	10.1016/j.phymed.2021.153802	Myricetin exhibit selective anti-lymphoma activity by targeting BTK and is effective via oral administration in vivo.	MTOR
34700229	10.1016/j.biopha.2021.112349	Rapamycin attenuates PLA2R activation-mediated podocyte apoptosis via the PI3K/AKT/mTOR pathway.	MTOR
34692691	10.3389/fcell.2021.734818	TEOA Promotes Autophagic Cell Death via ROS-Mediated Inhibition of mTOR/p70S6k Signaling Pathway in Pancreatic Cancer Cells.	MTOR
34673128	10.1016/j.canlet.2021.10.018	Metronomic chemotherapy regimens and targeted therapies in non-Hodgkin lymphoma: The best of two worlds.	MTOR
34670357	10.3324/haematol.2021.278796	Either IL-7 activation of JAK-STAT or BEZ inhibition of PI3K-AKT-mTOR pathways dominates the single-cell phosphosignature of <i>ex vivo</i> treated pediatric T-cell acute lymphoblastic leukemia cells.	MTOR
34669944	10.1093/mtomcs/mfab058	Maternal selenium deficiency suppresses proliferation, induces autophagy dysfunction and apoptosis in the placenta of mice.	MTOR
34659910		Post-transplant lymphoproliferative disorders (PTLD)-from clinical to metabolic profiles-a single center experience and review of literature.	MTOR
34658308	10.1080/21655979.2021.1977557	Transcription factor 3 (TCF3) combined with histone deacetylase 3 (HDAC3) down-regulates microRNA-101 to promote Burkitt lymphoma cell proliferation and inhibit apoptosis.	MTOR
34651869	10.1002/hon.2933	The resistance mechanisms and treatment strategies of BTK inhibitors in B-cell lymphoma.	MTOR
34643126	10.1080/07357907.2021.1983584	Phase II Study of Single-Agent and Combination Everolimus and Panobinostat in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.	MTOR
34624079	10.1182/blood.2021012081	SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma.	MTOR
34606736	10.1080/14728222.2021.1988927	Implications of recent molecular achievements in early diagnosis and precision treatments for primary CNS lymphoma.	MTOR
34589671	10.1097/HS9.0000000000000636	The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL - Results From the Phase-II STORM Trial.	MTOR
34589395	10.1016/j.apsb.2020.12.020	Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management.	MTOR
34579773	10.1186/s13578-021-00688-0	Metabolic reprogramming and metabolic sensors in KSHV-induced cancers and KSHV infection.	MTOR
34557659	10.1016/j.isci.2021.102931	The BTK/PI3K/BRD4 axis inhibitor SRX3262 overcomes Ibrutinib resistance in mantle cell lymphoma.	MTOR
34540765	10.3389/fped.2021.703853	Case Report: EBV Chronic Infection and Lymphoproliferation in Four APDS Patients: The Challenge of Proper Characterization, Therapy, and Follow-Up.	MTOR
34528236	10.1111/bjd.20760	Transcriptomic changes during stage progression of mycosis fungoides.	MTOR
34439483	10.3390/antiox10081235	Anthocyanins Promote Learning through Modulation of Synaptic Plasticity Related Proteins in an Animal Model of Ageing.	MTOR
34426436	10.1158/1078-0432.CCR-21-0573	Genome-Wide miRNA Expression Profiling of Molecular Subgroups of Peripheral T-cell Lymphoma.	MTOR
34410900	10.1080/13880209.2021.1961825	Anticancer effect of myristicin on hepatic carcinoma and related molecular mechanism.	MTOR
34403880	10.1016/j.neo.2021.07.009	Oncogene-independent resistance in Philadelphia chromosome - positive (Ph<sup>+</sup>) acute lymphoblastic leukemia (ALL) is mediated by activation of AKT/mTOR pathway.	MTOR
34386317	10.1016/j.apsb.2020.10.018	Natural compounds modulate the autophagy with potential implication of stroke.	MTOR
34320785	10.3324/haematol.2021.278853	Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas.	MTOR
34311319	10.1016/j.jinorgbio.2021.111550	Iridium(III)-BBIP complexes induce apoptosis via PI3K/AKT/mTOR pathway and inhibit A549 lung tumor growth in vivo.	MTOR
34277781	10.21037/atm-21-2574	A novel peptide promotes human trophoblast proliferation and migration through PI3K/Akt/mTOR signaling pathway.	MTOR
34277771	10.21037/atm-21-2360	Norcantharidin triggers apoptotic cell death in non-small cell lung cancer via a mitophagy-mediated autophagy pathway.	MTOR
34260908	10.1016/j.celrep.2021.109372	Inhibition of Rag GTPase signaling in mice suppresses B cell responses and lymphomagenesis with minimal detrimental trade-offs.	MTOR
34221985	10.3389/fonc.2021.670275	Combined Inhibition of Akt and mTOR Is Effective Against Non-Hodgkin Lymphomas.	MTOR
34219464	10.1139/bcb-2021-0045	Isovitexin attenuates tumor growth in human colon cancer cells through the modulation of apoptosis and epithelial-mesenchymal transition via PI3K/Akt/mTOR signaling pathway.	MTOR
34193976	10.1038/s41375-021-01326-x	Activated interleukin-7 receptor signaling drives B-cell acute lymphoblastic leukemia in mice.	MTOR
34162911	10.1038/s41598-021-92448-w	Focused CRISPR-Cas9 genetic screening reveals USO1 as a vulnerability in B-cell acute lymphoblastic leukemia.	MTOR
34162179	10.3324/haematol.2021.278743	Response and resistance to CDK12 inhibition in aggressive B-cell lymphomas.	MTOR
34159086	10.21037/tau-21-280	The protective effects of exogenous spermine on renal ischemia-reperfusion injury in rats.	MTOR
34139193	10.1016/j.ajpath.2021.06.004	Rictor/Mammalian Target of Rapamycin Complex 2 Signaling Protects Colonocytes from Apoptosis and Prevents Epithelial Barrier Breakdown.	MTOR
34132378	10.3892/ijo.2021.5232	Traditional and emerging therapies for anaplastic large cell lymphoma (Review).	MTOR
34119916	10.1016/j.intimp.2021.107829	Combination of Gemcitabine and Thymosin alpha 1 exhibit a better anti-tumor effect on nasal natural killer/T-cell lymphoma.	MTOR
34116237	10.1016/j.jshs.2021.06.002	Exercise attenuates angiotensinⅡ-induced muscle atrophy by targeting PPARγ/miR-29b.	MTOR
34115902	10.1111/ced.14798	The novel AKT inhibitor afuresertib suppresses human Merkel cell carcinoma MKL-1 cell growth.	MTOR
34080325	10.1002/cam4.4024	The genomic landscape of teenage and young adult T-cell acute lymphoblastic leukemia.	MTOR
34074205	10.1080/15548627.2021.1936932	Silencing PEX26 as an unconventional mode to kill drug-resistant cancer cells and forestall drug resistance.	MTOR
34070951	10.3390/diagnostics11060999	Diagnostic and Prognostic Value of Circulating Cell-Free DNA for Cholangiocarcinoma.	MTOR
34043588	10.1172/JCI139675	Chronic T cell receptor stimulation unmasks NK receptor signaling in peripheral T cell lymphomas via epigenetic reprogramming.	MTOR
34014537	10.1007/978-3-030-65768-0_7	Non-Hodgkin Lymphoma Metabolism.	MTOR
33994361	10.21873/cgp.20265	Clear Cell Renal Carcinoma: MicroRNAs With Efficacy in Preclinical <i>In Vivo</i> Models.	MTOR
33970999	10.1182/blood.2019000553	Overexpression of wild-type IL-7Rα promotes T-cell acute lymphoblastic leukemia/lymphoma.	MTOR
33954056	10.7717/peerj.11264	Melatonin ameliorates myocardial injury by reducing apoptosis and autophagy of cardiomyocytes in a rat cardiopulmonary bypass model.	MTOR
33939091	10.1007/s11356-021-14049-4	Morin protects against acrylamide-induced neurotoxicity in rats: an investigation into different signal pathways.	MTOR
33923420	10.3390/ncrna7020026	Exon-Intron Differential Analysis Reveals the Role of Competing Endogenous RNAs in Post-Transcriptional Regulation of Translation.	MTOR
33907223	10.1038/s41598-021-87966-6	ALK inhibition activates LC3B-independent, protective autophagy in EML4-ALK positive lung cancer cells.	MTOR
33890833	10.1080/1744666X.2021.1919085	Novel therapeutic approaches for cutaneous T cell lymphomas.	MTOR
33876224	10.1182/blood.2020008955	A novel and highly effective mitochondrial uncoupling drug in T-cell leukemia.	MTOR
33850273	10.1038/s41401-021-00643-2	P300/CBP inhibition sensitizes mantle cell lymphoma to PI3Kδ inhibitor idelalisib.	MTOR
33838212	10.1016/j.brainresbull.2021.04.003	Hydrogen-saturated saline mediated neuroprotection through autophagy via PI3K/AKT/mTOR pathway in early and medium stages of rotenone-induced Parkinson's disease rats.	MTOR
33821934	10.1093/abbs/gmab031	Anti-DLBCL efficacy of DCZ0825 in vitro and in vivo: involvement of the PI3K‒AKT‒mTOR/JNK pathway.	MTOR
33812443	10.19746/j.cnki.issn.1009-2137.2021.02.052	[New Advances in the Treatment of Primary Central Nervous System Lymphoma--Review].	MTOR
33793828	10.1093/jpp/rgaa018	Hypericin-mediated photodynamic therapy for the treatment of cancer: a review.	MTOR
33793811	10.1093/jpp/rgaa011	Eupafolin induces autophagy and apoptosis in B-cell non-Hodgkin lymphomas.	MTOR
33790574	10.2147/OTT.S189032	Oral PI3K-δ,γ Inhibitor for the Management of People with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Narrative Review on Duvelisib.	MTOR
33787984	10.1007/s00277-021-04493-0	High-throughput proteomic profiling reveals mechanisms of action of AMG925, a dual FLT3-CDK4/6 kinase inhibitor targeting AML and AML stem/progenitor cells.	MTOR
33784031	10.1002/cnr2.1372	Mixed phenotype acute leukemia in a child associated with a NUP98-NSD1 fusion and NRAS p.Gly61Arg mutation.	MTOR
33782541	10.1038/s41401-021-00644-1	SAF-248, a novel PI3Kδ-selective inhibitor, potently suppresses the growth of diffuse large B-cell lymphoma.	MTOR
33777762	10.3389/fonc.2021.618908	CS2164 and Venetoclax Show Synergistic Antitumoral Activities in High Grade B-Cell Lymphomas With <i>MYC</i> and <i>BCL2</i> Rearrangements.	MTOR
33774181	10.1016/j.phrs.2021.105579	Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies.	MTOR
33747367	10.4081/oncol.2021.514	Metformin - its anti-cancer effects in hematologic malignancies.	MTOR
33730679	10.1016/j.tranon.2021.101068	MicroRNA-181a suppresses norethisterone-promoted tumorigenesis of breast epithelial MCF10A cells through the PGRMC1/EGFR-PI3K/Akt/mTOR signaling pathway.	MTOR
33729497	10.1042/CS20201296	Brain angiotensin system: a new promise in the management of epilepsy?	MTOR
33705488	10.1371/journal.pone.0248298	Ruxolitinib with resminostat exert synergistic antitumor effects in Cutaneous T-cell Lymphoma.	MTOR
33668434	10.3390/molecules26040987	Anti-Cancer Properties of Theaflavins.	MTOR
33664464	10.1038/s41375-021-01191-8	Targeted based therapy in nodal T-cell lymphomas.	MTOR
33641784	10.1016/S1875-5364(21)60014-6	Artemisia kruhsiana leaf extract induces autophagic cell death in human prostate cancer cells.	MTOR
33641344	10.1139/cjpp-2020-0487	mTOR inhibition as a possible pharmacological target in the management of systemic inflammatory response and associated neuroinflammation by lipopolysaccharide challenge in rats.	MTOR
33619116	10.1158/0008-5472.CAN-20-2297	NPM-ALK-Induced Reprogramming of Mature TCR-Stimulated T Cells Results in Dedifferentiation and Malignant Transformation.	MTOR
33615686	10.1002/kjm2.12352	The depletion of Circ-PRKDC enhances autophagy and apoptosis in T-cell acute lymphoblastic leukemia via microRNA-653-5p/Reelin mediation of the PI3K/AKT/mTOR signaling pathway.	MTOR
33611674	10.1007/s11010-021-04098-1	Long non-coding RNA GAS5 suppresses rheumatoid arthritis progression via miR-128-3p/HDAC4 axis.	MTOR
33605486	10.1113/EP089328	Endogenous production of n-3 polyunsaturated fatty acids protects mice from carbon tetrachloride-induced liver fibrosis by regulating mTOR and Bcl-2/Bax signalling pathways.	MTOR
33570607	10.1182/blood.2020008465	Synergy of MALT1 and mTOR inhibition in DLBCL.	MTOR
33567641	10.3390/cancers13040682	Genomic Landscape of Hodgkin Lymphoma.	MTOR
33559856	10.1007/978-3-030-55617-4_5	IL-22 Signaling in the Tumor Microenvironment.	MTOR
33531656	10.1038/s41375-021-01132-5	Dual targeting of MTOR as a novel therapeutic approach for high-risk B-cell acute lymphoblastic leukemia.	MTOR
33530027	10.1016/j.tranon.2021.101027	STRN-ALK rearranged pediatric malignant peritoneal mesothelioma - Functional testing of 527 cancer drugs in patient-derived cancer cells.	MTOR
33506273	10.1007/s00520-021-06016-z	Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practice.	MTOR
33496749	10.1182/bloodadvances.2020002832	Hypoxia favors chemoresistance in T-ALL through an HIF1α-mediated mTORC1 inhibition loop.	MTOR
33489922	10.3389/fonc.2020.611690	The Role of mTOR Inhibitors in Hematologic Disease: From Bench to Bedside.	MTOR
33484281	10.1007/s00109-020-02020-8	3D culture conditions support Kaposi's sarcoma herpesvirus (KSHV) maintenance and viral spread in endothelial cells.	MTOR
33475938	10.1007/s10637-021-01066-w	AD80, a multikinase inhibitor, exhibits antineoplastic effects in acute leukemia cellular models targeting the PI3K/STMN1 axis.	MTOR
33450375	10.1016/j.freeradbiomed.2020.12.452	Oxygen sensing, mitochondrial biology and experimental therapeutics for pulmonary hypertension and cancer.	MTOR
33412518	10.18632/aging.202462	Function of Deptor and its roles in hematological malignancies.	MTOR
33393503	10.1172/JCI133090	BCL6 confers KRAS-mutant non-small-cell lung cancer resistance to BET inhibitors.	MTOR
33391513	10.7150/thno.46655	LncRNA BCYRN1-induced autophagy enhances asparaginase resistance in extranodal NK/T-cell lymphoma.	MTOR
33318657	10.1038/s41416-020-01205-9	Targeting eIF4F translation initiation complex with SBI-756 sensitises B lymphoma cells to venetoclax.	MTOR
33311569	10.1038/s41417-020-00267-4	LncRNA LINC01857 promotes cell growth and diminishes apoptosis via PI3K/mTOR pathway and EMT process by regulating miR-141-3p/MAP4K4 axis in diffuse large B-cell lymphoma.	MTOR
33304974	10.1016/j.jdcr.2020.08.041	Primary cutaneous peripheral T-cell lymphoma, not otherwise specified with mammalian target of rapamycin mutation: A novel finding for targeted treatment.	MTOR
33300153	10.1002/hon.2831	Growth inhibition and suppression of the mTOR and Wnt/β-catenin pathways in T-acute lymphoblastic leukemia by rapamycin and MYCN depletion.	MTOR
33251904	10.1080/10428194.2020.1849679	The regulation of bcr-abl in hypoxia is through the mTOR pathway.	MTOR
33246167	10.1016/j.phrs.2020.105302	Cannabis and its constituents for cancer: History, biogenesis, chemistry and pharmacological activities.	MTOR
35753740	10.11817/j.issn.1672-7347.2020.190291	Effect of salvianolic acid A on the proliferation and apoptosis in esophageal cancer cells and the underlying mechanisms.	MTOR
33206174	10.1093/carcin/bgaa119	Synergistic targeting of CHK1 and mTOR in MYC-driven tumors.	MTOR
33191863	10.1080/16078454.2020.1845501	Blockade of PLD1 potentiates the antitumor effects of bortezomib in multiple myeloma cells by inhibiting the mTOR/NF-κB signal pathway.	MTOR
33154951	10.3389/fonc.2020.591577	Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies.	MTOR
33154093	10.1158/1541-7786.MCR-20-0466	Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents.	MTOR
33109547	10.21873/anticanres.14630	Inhibition of Bruton's Tyrosine Kinase Suppresses Cancer Stemness and Promotes Carboplatin-induced Cytotoxicity Against Bladder Cancer Cells.	MTOR
33055173	10.1158/1078-0432.CCR-20-1215	Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma.	MTOR
33053749	10.3390/cancers12102936	The In Vitro and In Vivo Anticancer Properties of Chalcone Flavokawain B through Induction of ROS-Mediated Apoptotic and Autophagic Cell Death in Human Melanoma Cells.	MTOR
33049974	10.3390/antiox9100961	Anticancer Properties of Carnosol: A Summary of in Vitro and In Vivo Evidence.	MTOR
33044904	10.1080/15548627.2020.1821548	BNIP3L/Nix-induced mitochondrial fission, mitophagy, and impaired myocyte glucose uptake are abrogated by PRKA/PKA phosphorylation.	MTOR
33037136	10.1158/1535-7163.MCT-19-0973	Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4A.	MTOR
33029053	10.1016/j.jceh.2020.02.001	De Novo Malignancy After Living Donor Liver Transplantation: A Large Volume Experience.	MTOR
33020261	10.1073/pnas.2008883117	The transcription factor C/EBPβ orchestrates dendritic cell maturation and functionality under homeostatic and malignant conditions.	MTOR
32999755	10.1186/s40164-020-00182-2	miR-100 inhibits cell proliferation in mantle cell lymphoma by targeting mTOR.	MTOR
32989257	10.1038/s41388-020-01469-8	Increased baseline RASGRP1 signals enhance stem cell fitness during native hematopoiesis.	MTOR
32970929	10.1111/ajco.13449	Role and mechanism of autophagy-regulating factors in tumorigenesis and drug resistance.	MTOR
32961236	10.1016/j.lfs.2020.118467	Retinoprotective effect of donepezil in diabetic mice involves mitigation of excitotoxicity and activation of PI3K/mTOR/BCl<sub>2</sub> pathway.	MTOR
32943998	10.1186/s12935-020-01539-7	HKDC1 promotes the tumorigenesis and glycolysis in lung adenocarcinoma via regulating AMPK/mTOR signaling pathway.	MTOR
32926124	10.1182/bloodadvances.2020001685	Targeting phosphatidylinositol 3 kinase-β and -δ for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma.	MTOR
32915799	10.1371/journal.pone.0238379	Proteomic and transcriptomic studies of BGC823 cells stimulated with Helicobacter pylori isolates from gastric MALT lymphoma.	MTOR
32913370	10.1371/journal.pone.0239102	Retraction: Simultaneous Inhibition of mTOR-Containing Complex 1 (mTORC1) and MNK Induces Apoptosis of Cutaneous T-Cell Lymphoma (CTCL) Cells.	MTOR
32898863	10.1182/blood.2020005622	Identification of functional cooperative mutations of GNAO1 in human acute lymphoblastic leukemia.	MTOR
32835548	10.1080/10428194.2020.1804560	SIX6 is a TAL1-regulated transcription factor in T-ALL and associated with inferior outcome.	MTOR
32804454	10.1097/PAS.0000000000001512	Colorectal Adenocarcinomas Harboring ALK Fusion Genes: A Clinicopathologic and Molecular Genetic Study of 12 Cases and Review of the Literature.	MTOR
32803259	10.1042/CS20200514	Antiepileptic effects of long-term intracerebroventricular infusion of angiotensin-(1-7) in an animal model of temporal lobe epilepsy.	MTOR
32800789	10.1016/j.pharmthera.2020.107659	Molecular mechanisms and therapeutic implications of tetrandrine and cepharanthine in T cell acute lymphoblastic leukemia and autoimmune diseases.	MTOR
32776229	10.1007/s00280-020-04122-z	miR-331-3p is involved in glucocorticoid resistance reversion by rapamycin through suppression of the MAPK signaling pathway.	MTOR
32763229	10.1016/j.hemonc.2020.07.007	Molecular events and cytotoxic effects of a novel thiosemicarbazone derivative in human leukemia and lymphoma cell lines.	MTOR
32753387	10.1158/1535-7163.MCT-20-0160	PIM Kinase Inhibitors Block the Growth of Primary T-cell Acute Lymphoblastic Leukemia: Resistance Pathways Identified by Network Modeling Analysis.	MTOR
32749680	10.1002/jcp.29943	Light-emitting diode irradiation induces AKT/mTOR-mediated apoptosis in human pancreatic cancer cells and xenograft mouse model.	MTOR
32747423	10.1158/1535-7163.MCT-19-0671	Hypomorphic mTOR Downregulates CDK6 and Delays Thymic Pre-T LBL Tumorigenesis.	MTOR
32733473	10.3389/fimmu.2020.01423	From Cancer to Immune-Mediated Diseases and Tolerance Induction: Lessons Learned From Immune Oncology and Classical Anti-cancer Treatment.	MTOR
32731591	10.3390/cancers12082099	Oxidative Stress and Apoptotic Responses Elicited by <i>Nostoc</i>-Synthesized Silver Nanoparticles against Different Cancer Cell Lines.	MTOR
32702393	10.1016/j.exphem.2020.07.005	DEPTOR is a microRNA-155 target regulating migration and cytokine production in diffuse large B-cell lymphoma cells.	MTOR
32682197	10.1016/j.ejmech.2020.112582	New insight into 20(S)-ginsenoside Rh2 against T-cell acute lymphoblastic leukemia associated with the gut microbiota and the immune system.	MTOR
32671779	10.1007/978-981-15-4272-5_44	Autophagy and Lymphoma.	MTOR
32665551	10.1038/s41467-020-17064-0	PRDM15 is a key regulator of metabolism critical to sustain B-cell lymphomagenesis.	MTOR
32627816	10.1042/BSR20193738	Ma xing shi gan decoction eliminates PM2.5-induced lung injury by reducing pulmonary cell apoptosis through Akt/mTOR/p70S6K pathway in rats.	MTOR
32615949	10.1186/s12885-020-07102-x	Etoposide-mediated interleukin-8 secretion from bone marrow stromal cells induces hematopoietic stem cell mobilization.	MTOR
32601796	10.1007/s00277-020-04159-3	Safety and efficacy of temsirolimus in combination with three different immuno-chemotherapy regimens in relapse and refractory mantle cell lymphoma, final results of the T<sup>3</sup> phase IB trial of the LYSA.	MTOR
32586008	10.3390/biomedicines8060170	ROR1 Is Expressed in Diffuse Large B-Cell Lymphoma (DLBCL) and a Small Molecule Inhibitor of ROR1 (KAN0441571C) Induced Apoptosis of Lymphoma Cells.	MTOR
32566584	10.21037/atm-20-3768	Beta carotene protects H9c2 cardiomyocytes from advanced glycation end product-induced endoplasmic reticulum stress, apoptosis, and autophagy via the PI3K/Akt/mTOR signaling pathway.	MTOR
32546661	10.1158/1535-7163.MCT-19-1111	A Novel Approach to Safer Glucocorticoid Receptor-Targeted Anti-lymphoma Therapy via REDD1 (Regulated in Development and DNA Damage 1) Inhibition.	MTOR
32508655	10.3389/fphar.2020.00737	CCT020312 Inhibits Triple-Negative Breast Cancer Through PERK Pathway-Mediated G1 Phase Cell Cycle Arrest and Apoptosis.	MTOR
32495867	10.26355/eurrev_202005_21316	Metformin reduces pancreatic cancer cell proliferation and increases apoptosis through MTOR signaling pathway and its dose-effect relationship.	MTOR
32487610	10.21873/anticanres.14297	Sirtuin 1 Activation Suppresses the Growth of T-lymphoblastic Leukemia Cells by Inhibiting NOTCH and NF-κB Pathways.	MTOR
32479694	10.1002/cyto.b.21882	Single-cell profiling of pediatric T-cell acute lymphoblastic leukemia: Impact of PTEN exon 7 mutation on PI3K/Akt and JAK-STAT signaling pathways.	MTOR
32468878	10.1177/0300060520926093	BI6727, a polo-like kinase 1 inhibitor with promising efficacy on Burkitt lymphoma cells.	MTOR
32427409	10.1002/gcc.22861	Targeted next generation sequencing of MLH1-deficient, MLH1 promoter hypermethylated, and BRAF/RAS-wild-type colorectal adenocarcinomas is effective in detecting tumors with actionable oncogenic gene fusions.	MTOR
32416683	10.2174/1871527319666200517112252	Targeting the PI3K/AKT/mTOR Signaling Pathway in Primary Central Nervous System Lymphoma: Current Status and Future Prospects.	MTOR
32359574	10.1016/j.psj.2019.10.034	Gut microbiota mediates the protective role of Lactobacillus plantarum in ameliorating deoxynivalenol-induced apoptosis and intestinal inflammation of broiler chickens.	MTOR
32356174	10.1007/s11864-020-00746-8	PI3K Inhibitors and Their Role as Novel Agents for Targeted Therapy in Lymphoma.	MTOR
32334988	10.1016/j.idc.2020.02.005	Epidermal Growth Factor Receptor Inhibitors and Other Tyrosine Kinase Inhibitors for Solid Tumors.	MTOR
32270047	10.1126/sciadv.aaz9798	Pretargeted delivery of PI3K/mTOR small-molecule inhibitor-loaded nanoparticles for treatment of non-Hodgkin's lymphoma.	MTOR
32255708	10.1080/10428194.2020.1747068	Burkitt lymphoma: bridging the gap between advances in molecular biology and therapy.	MTOR
32240637	10.1016/j.abb.2020.108352	Rab1A knockdown represses proliferation and promotes apoptosis in gastric cancer cells by inhibition of mTOR/p70S6K pathway.	MTOR
32235787	10.3390/ijms21062193	The Current Genomic and Molecular Landscape of Philadelphia-like Acute Lymphoblastic Leukemia.	MTOR
32231197	10.32471/exp-oncology.2312-8852.vol-42-no-1.14067	Rapamycin-induced autophagy plays a pro-survival role by enhancing up-regulation of intracellular ferritin expression in acute lymphoblastic leukemia.	MTOR
32219060	10.3389/fonc.2020.00217	Apatinib Inhibits Cell Proliferation and Induces Autophagy in Human Papillary Thyroid Carcinoma via the PI3K/Akt/mTOR Signaling Pathway.	MTOR
32206779	10.1182/blood.2019002792	Increased mTOR activation in idiopathic multicentric Castleman disease.	MTOR
32185137	10.3389/fonc.2020.00273	The Physiopathology of T- Cell Acute Lymphoblastic Leukemia: Focus on Molecular Aspects.	MTOR
32179489	10.1016/j.cancergen.2020.02.005	Integrating transcriptome-wide association study and copy number variation study identifies candidate genes and pathways for diffuse non-Hodgkin's lymphoma.	MTOR
32171983	10.1016/j.bioorg.2020.103724	Synthesis and biological evaluation of 6-phenylpurine linked hydroxamates as novel histone deacetylase inhibitors.	MTOR
32164676	10.1186/s12906-020-2846-4	Total flavones of Dracocephalum moldavica L. protect astrocytes against H<sub>2</sub>O<sub>2</sub>-induced apoptosis through a mitochondria-dependent pathway.	MTOR
32154751	10.1080/10428194.2020.1734594	IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia.	MTOR
32149078	10.1155/2020/1520651	Autophagy Inhibition Potentiates the Anticancer Effects of a Bendamustine Derivative NL-101 in Acute T Lymphocytic Leukemia.	MTOR
32145743	10.1186/s12906-020-2865-1	Germacrone protects against oxygen-glucose deprivation/reperfusion injury by inhibiting autophagy processes in PC12 cells.	MTOR
32145384	10.1016/j.exphem.2020.02.004	Tumor-specific transcript variants of cyclin D1 in mantle cell lymphoma and multiple myeloma with chromosome 11q13 abnormalities.	MTOR
32140387	10.1016/j.apsb.2019.06.005	Disturbed Yin-Yang balance: stress increases the susceptibility to primary and recurrent infections of herpes simplex virus type 1.	MTOR
32132036	10.21873/anticanres.14081	Synergistic Effect of Alectinib and Everolimus on ALK-positive Anaplastic Large Cell Lymphoma Growth Inhibition.	MTOR
32131560	10.3390/nu12030679	Mechanism of Anti-Cancer Activity of Curcumin on Androgen-Dependent and Androgen-Independent Prostate Cancer.	MTOR
32127939	10.7150/jca.34981	Apigenin and Abivertinib, a novel BTK inhibitor synergize to inhibit diffuse large B-cell lymphoma <i>in vivo and vitro</i>.	MTOR
32108030	10.1158/1078-0432.CCR-18-3851	Metabolome Analysis Reveals Excessive Glycolysis via PI3K/AKT/mTOR and RAS/MAPK Signaling in Methotrexate-Resistant Primary CNS Lymphoma-Derived Cells.	MTOR
32104214	10.3892/etm.2019.8398	Ghrelin inhibits cisplatin-induced MDA-MB-231 breast cancer cell apoptosis via PI3K/Akt/mTOR signaling.	MTOR
32098126	10.3390/molecules25040971	Benzoxazole Derivative K313 Induces Cell Cycle Arrest, Apoptosis and Autophagy Blockage and Suppresses mTOR/p70S6K Pathway in Nalm-6 and Daudi Cells.	MTOR
32074729	10.3760/cma.j.issn.0529-5807.2020.02.010	[Expression of p-AKT and p-mTOR in pediatric Burkitt lymphoma and their correlation with prognosis].	MTOR
32064003	10.1177/1758835919897546	Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer.	MTOR
32047535	10.1177/1758835919895756	Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion.	MTOR
32033478	10.3390/ijms21031060	Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?	MTOR
32014673	10.1016/j.critrevonc.2020.102886	Mechanisms of resistance to mTOR inhibitors.	MTOR
32009599	10.2174/1871520619666190925143216	Signal Pathways and Therapeutic Prospects of Diffuse Large B Cell Lymphoma.	MTOR
31980182	10.1016/j.bbrc.2019.12.129	Curcumin exerts anti-tumor effects on diffuse large B cell lymphoma via regulating PPARγ expression.	MTOR
31950225	10.1007/s00262-020-02482-2	CD16 pre-ligation by defucosylated tumor-targeting mAb sensitizes human NK cells to γ<sub>c</sub> cytokine stimulation via PI3K/mTOR axis.	MTOR
31934105		EBV-associated myoid tumor with lipoblast-like cells in a patient with normal immunity.	MTOR
31912905	10.1002/jcp.29443	Neratinib degrades MST4 via autophagy that reduces membrane stiffness and is essential for the inactivation of PI3K, ERK1/2, and YAP/TAZ signaling.	MTOR
31904116	10.1002/jcp.29429	Targeting Wnt/β-catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia.	MTOR
31894340	10.3892/or.2019.7453	Tanshinone IIA enhances the inhibitory effect of imatinib on proliferation and motility of acute leukemia cell line TIB‑152 in vivo and in vitro by inhibiting the PI3K/AKT/mTOR signaling pathway.	MTOR
35356005	10.31491/apt.2020.03.009	Thioredoxin overexpression in mitochondria showed minimum effects on aging and age-related diseases in male C57BL/6 mice.	MTOR
31883669	10.1016/j.pathol.2019.09.014	The clinicopathological and genetic features of ovarian diffuse large B-cell lymphoma.	MTOR
31881325	10.1016/j.cellsig.2019.109518	Apoptosis and autophagy in polycystic kidney disease (PKD).	MTOR
31866476	10.1016/j.semcancer.2019.12.008	Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy.	MTOR
31853198	10.2147/CMAR.S208720	First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy.	MTOR
31839994	10.1038/s41420-019-0231-1	A cysteine near the C-terminus of UCH-L1 is dispensable for catalytic activity but is required to promote AKT phosphorylation, eIF4F assembly, and malignant B-cell survival.	MTOR
31827726	10.18632/oncotarget.27309	Correction: Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1.	MTOR
31827702	10.1155/2019/7989276	Enhancement of Quercetin-Induced Apoptosis by Cotreatment with Autophagy Inhibitor Is Associated with Augmentation of BAK-Dependent Mitochondrial Pathway in Jurkat T Cells.	MTOR
31774495	10.1182/blood.2019001904	Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL.	MTOR
31774199	10.15252/embj.2019102030	Paracaspase MALT1 regulates glioma cell survival by controlling endo-lysosome homeostasis.	MTOR
31772298	10.1038/s41375-019-0663-x	Interaction kinetics with transcriptomic and secretory responses of CD19-CAR natural killer-cell therapy in CD20 resistant non-hodgkin lymphoma.	MTOR
31742861	10.1111/jcmm.14810	TPD7 inhibits the growth of cutaneous T cell lymphoma H9 cell through regulating IL-2R signalling pathway.	MTOR
31714156	10.1080/14712598.2020.1688298	NK cell-based therapeutics for lung cancer.	MTOR
31712222	10.1101/cshperspect.a036244	PTEN in Regulating Hematopoiesis and Leukemogenesis.	MTOR
31698306	10.1016/j.leukres.2019.106229	Gene expression profiling by mRNA sequencing reveals dysregulation of core genes in Rictor deficient T-ALL mouse model.	MTOR
31682844	10.1016/j.jid.2019.08.454	Preclinical Evidence for Targeting PI3K/mTOR Signaling with Dual-Inhibitors as a Therapeutic Strategy against Cutaneous T-Cell Lymphoma.	MTOR
31679027	10.1093/jas/skz339	Dietary supplementation with free methionine or methionine dipeptide improves environment intestinal of broilers challenged with Eimeria spp.	MTOR
31676945	10.1007/s00403-019-02000-0	Molecular profiling of TOX-deficient neoplastic cells in cutaneous T cell lymphoma.	MTOR
31638226	10.3892/mmr.2019.10756	Antitumor effects and mechanisms of 1,25(OH)2D3 in the Pfeiffer diffuse large B lymphoma cell line.	MTOR
31636099	10.1158/1078-0432.CCR-19-1486	Colony-Stimulating Factor 1 Receptor (CSF1R) Activates AKT/mTOR Signaling and Promotes T-Cell Lymphoma Viability.	MTOR
31628323	10.1038/s41467-019-12656-x	A kinase-independent role for CDK8 in BCR-ABL1<sup>+</sup> leukemia.	MTOR
31619091	10.1080/17474086.2020.1681962	Contemporary management of nodal and primary splenic marginal zone lymphoma.	MTOR
31587272	10.1002/jcp.29218	Organic anion transporters and PI3K-AKT-mTOR pathway mediate the synergistic anticancer effect of pemetrexed and rhein.	MTOR
31585938	10.1158/1078-0432.CCR-19-1104	Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.	MTOR
31579886	10.1038/s42255-019-0098-8	Oncogenic Rag GTPase signaling enhances B cell activation and drives follicular lymphoma sensitive to pharmacological inhibition of mTOR.	MTOR
31552092	10.3389/fgene.2019.00780	Transcriptional Analysis of Lennert Lymphoma Reveals a Unique Profile and Identifies Novel Therapeutic Targets.	MTOR
31533276	10.3390/genes10090718	Allele-Specific Expression of CD4<sup>+</sup> T Cells in Response to Marek's Disease Virus Infection.	MTOR
31524260	10.3892/mmr.2019.10514	Complement factor H‑related 3 overexpression affects hepatocellular carcinoma proliferation and apoptosis.	MTOR
31508518	10.1016/j.heliyon.2019.e02290	Pre-clinical anti-tumor activity of Bruton's Tyrosine Kinase inhibitor in Hodgkin's Lymphoma cellular and subcutaneous tumor model.	MTOR
31498006	10.1080/21691401.2019.1645151	Long noncoding RNA HAGLROS promotes the process of mantle cell lymphoma by regulating miR-100/ATG5 axis and involving in PI3K/AKT/mTOR signal.	MTOR
31497243	10.18632/oncotarget.27154	Walking the tightrope: UCH-L1 as an mTOR inhibitor and B-cell oncogene.	MTOR
31492675	10.1182/blood.2019000015	Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemia.	MTOR
31464204	10.4103/aja.aja_89_19	Effect of probucol on autophagy and apoptosis in the penile tissue of streptozotocin-induced diabetic rats.	MTOR
31448672	10.1080/15548627.2019.1659654	PAQR3 suppresses the growth of non-small cell lung cancer cells via modulation of EGFR-mediated autophagy.	MTOR
31411791	10.1111/jog.14079	Effects of microRNA-1271 on ovarian cancer via inhibition of epithelial-mesenchymal transition and cisplatin resistance.	MTOR
31391255	10.1074/jbc.RA119.009551	Coordinated regulation of scaffold opening and enzymatic activity during CARD11 signaling.	MTOR
31351435	10.1016/j.biopha.2019.109241	Huachansu Capsule inhibits the proliferation of human gastric cancer cells via Akt/mTOR pathway.	MTOR
31334109	10.3389/fonc.2019.00568	Dynamic Changes in Gene Mutational Landscape With Preservation of Core Mutations in Mantle Cell Lymphoma Cells.	MTOR
31332784	10.1002/jcp.28984	Silencing of RHEB inhibits cell proliferation and promotes apoptosis in colorectal cancer cells via inhibition of the mTOR signaling pathway.	MTOR
31310849	10.1016/j.fsi.2019.07.022	Chlorpyrifos induced oxidative stress to promote apoptosis and autophagy through the regulation of miR-19a-AMPK axis in common carp.	MTOR
31297833	10.1002/jcp.29060	Long noncoding RNA PVT1: A highly dysregulated gene in malignancy.	MTOR
31286804	10.1080/15548627.2019.1635384	New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.	MTOR
31281438	10.3892/etm.2019.7629	Knockdown of lncRNA-HOTAIR downregulates the drug-resistance of breast cancer cells to doxorubicin via the PI3K/AKT/mTOR signaling pathway.	MTOR
31262977	10.1042/BSR20182274	EPHA3 enhances macrophage autophagy and apoptosis by disrupting the mTOR signaling pathway in mice with endometriosis.	MTOR
31258692	10.3892/etm.2019.7589	Puerarin suppresses cell growth and migration in HPV-positive cervical cancer cells by inhibiting the PI3K/mTOR signaling pathway.	MTOR
31255635	10.1016/j.cbi.2019.108726	Tetrandrine and cepharanthine induce apoptosis through caspase cascade regulation, cell cycle arrest, MAPK activation and PI3K/Akt/mTOR signal modification in glucocorticoid resistant human leukemia Jurkat T cells.	MTOR
31242129	10.1080/15548627.2019.1635380	<i>MIR145-3p</i> promotes autophagy and enhances bortezomib sensitivity in multiple myeloma by targeting <i>HDAC4</i>.	MTOR
31238062	10.1016/j.ejphar.2019.172494	Comparative transcriptome analysis of peripheral blood mononuclear cells in renal transplant recipients in everolimus- and tacrolimus-based immunosuppressive therapy.	MTOR
31226848	10.3390/ijms20123021	Strategies to Overcome Resistance Mechanisms in T-Cell Acute Lymphoblastic Leukemia.	MTOR
31214498	10.3389/fonc.2019.00443	Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas.	MTOR
31202171	10.1016/j.biopha.2019.109071	Huaier extract enhances the treatment efficacy of imatinib in Ik6<sup>+</sup> Ph<sup>+</sup> acute lymphoblastic leukemia.	MTOR
31189740	10.1042/BSR20182196	microRNA-613 exerts anti-angiogenic effect on nasopharyngeal carcinoma cells through inactivating the AKT signaling pathway by down-regulating FN1.	MTOR
31181779	10.3390/molecules24112165	A Ferulic Acid Derivative FXS-3 Inhibits Proliferation and Metastasis of Human Lung Cancer A549 Cells via Positive JNK Signaling Pathway and Negative ERK/p38, AKT/mTOR and MEK/ERK Signaling Pathways.	MTOR
31173255	10.3892/mmr.2019.10369	Effect of metformin on cell proliferation, apoptosis, migration and invasion in A172 glioma cells and its mechanisms.	MTOR
31167506	10.3390/cancers11060775	The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax.	MTOR
31166253	10.1097/HJH.0000000000002139	Dysfunction of B-cell lymphoma 2/adenovirus E1B 19KD interacting protein 3 in decidua is involved in the pathogenesis of preeclampsia.	MTOR
31148590	10.1038/s41375-019-0486-9	The WNT receptor ROR2 drives the interaction of multiple myeloma cells with the microenvironment through AKT activation.	MTOR
31135975	10.1111/bjh.15997	Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma.	MTOR
31114980	10.26355/eurrev_201905_17778	MiR-29 regulates retinopathy in diabetic mice via the AMPK signaling pathway.	MTOR
31101621	10.1182/blood.2018874560	Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma.	MTOR
31058559	10.1080/10428194.2019.1607330	Epstein-Barr virus-encoded LMP1 induces ectopic CD137 expression on Hodgkin and Reed-Sternberg cells via the PI3K-AKT-mTOR pathway.	MTOR
31056348	10.1016/j.clml.2019.03.015	Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study.	MTOR
31042587	10.1016/j.canlet.2019.04.030	IGF1R/IRS1 targeting has cytotoxic activity and inhibits PI3K/AKT/mTOR and MAPK signaling in acute lymphoblastic leukemia cells.	MTOR
31036508	10.1016/j.clml.2019.03.017	Future of Personalized Therapy Targeting Aberrant Signaling Pathways in Multiple Myeloma.	MTOR
31028199	10.21873/invivo.11541	CCL21 Induces mTOR-dependent MALAT1 Expression, Leading to Cell Migration in Cutaneous T-Cell Lymphoma.	MTOR
31018830	10.1177/1010428319846803	Mesenchymal stem cells targeting PI3K/AKT pathway in leukemic model.	MTOR
30995847	10.14735/amko201990	Therapy of Relapsed/Refractory Acute Lymphoblastic Leukemia Today and Tomorrow.	MTOR
30990357	10.1080/15548627.2019.1607694	Cell quality control mechanisms maintain stemness and differentiation potential of P19 embryonic carcinoma cells.	MTOR
30988770	10.3892/etm.2019.7402	BOS-93, a novel bromophenol derivative, induces apoptosis and autophagy in human A549 lung cancer cells via PI3K/Akt/mTOR and MAPK signaling pathway.	MTOR
30973085	10.1080/01616412.2019.1596206	Rutin hydrate inhibits apoptosis in the brains of cadmium chloride-treated rats via preserving the mitochondrial integrity and inhibiting endoplasmic reticulum stress.	MTOR
30914027	10.2174/1568009619666190326120833	Inhibition of PI3K/mTOR Pathways with GDC-0980 in Pediatric Leukemia: Impact on Abnormal FLT-3 Activity and Cooperation with Intracellular Signaling Targets.	MTOR
30896875	10.3892/mmr.2019.10021	Knockdown of serpin peptidase inhibitor clade C member 1 inhibits the growth of nasopharyngeal carcinoma cells.	MTOR
30896824	10.3892/or.2019.7072	Timosaponin A‑III induces autophagy of T‑cell acute lymphoblastic leukemia Jurkat cells via inhibition of the PI3K/Akt/mTOR pathway.	MTOR
30880359	10.1007/s11899-019-00501-3	Relapsed T Cell ALL: Current Approaches and New Directions.	MTOR
30867372	10.5582/bst.2019.01006	Effects of BENC-511, a novel PI3K inhibitor, on the proliferation and apoptosis of A549 human lung adenocarcinoma cells.	MTOR
30864709	10.3892/mmr.2019.10002	Butyrate inhibits the proliferation and induces the apoptosis of colorectal cancer HCT116 cells via the deactivation of mTOR/S6K1 signaling mediated partly by SIRT1 downregulation.	MTOR
30864685	10.3892/ijmm.2019.4129	GNG7 silencing promotes the proliferation and differentiation of placental cytotrophoblasts in preeclampsia rats through activation of the mTOR signaling pathway.	MTOR
30854075	10.3892/ol.2019.9890	UNBS5162 inhibits SKOV3 ovarian cancer cell proliferation by regulating the PI3K/AKT signalling pathway.	MTOR
30845773	10.3390/biom9030092	[Pt(<i>O,O</i>'-acac)(γ-acac)(DMS)] Induces Autophagy in Caki-1 Renal Cancer Cells.	MTOR
30827861	10.1016/j.cmet.2019.02.002	GAPDH Expression Predicts the Response to R-CHOP, the Tumor Metabolic Status, and the Response of DLBCL Patients to Metabolic Inhibitors.	MTOR
30808136	10.13201/j.issn.1001-1781.2019.02.008	[Expression of mTOR and 4E-BP1 in extranodal Nasal-type NK/T-cell Lymphoma and implication for prognosis].	MTOR
30806286	10.1615/JEnvironPatholToxicolOncol.2018027885	Autophagy is Required to Regulate Mitochondria Renewal, Cell Attachment, and All-trans-Retinoic Acid-Induced Differentiation in NB4 Acute Promyelocytic Leukemia Cells.	MTOR
30801854	10.1002/biof.1498	ROR1 associates unfavorable prognosis and promotes lymphoma growth in DLBCL by affecting PI3K/Akt/mTOR signaling pathway.	MTOR
30798134	10.1016/j.biopha.2019.108599	Tanshinone IIA protects against heart failure post-myocardial infarction via AMPKs/mTOR-dependent autophagy pathway.	MTOR
30795552	10.3390/cells8020190	Targeting mTOR in Acute Lymphoblastic Leukemia.	MTOR
30782662	10.1128/mBio.02871-18	Targeting mTOR with MLN0128 Overcomes Rapamycin and Chemoresistant Primary Effusion Lymphoma.	MTOR
30782609	10.1182/blood-2018-09-872549	Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma.	MTOR
30763910	10.1016/j.neo.2019.01.004	Comprehensive Investigation of miRNome Identifies Novel Candidate miRNA-mRNA Interactions Implicated in T-Cell Acute Lymphoblastic Leukemia.	MTOR
30733891	10.1186/s40164-019-0126-0	Mantle cell lymphoma and its management: where are we now?	MTOR
30720463	10.1172/JCI98288	Follicular lymphoma-associated mutations in vacuolar ATPase ATP6V1B2 activate autophagic flux and mTOR.	MTOR
30718665	10.1038/s41598-018-37666-5	Oxo-aglaiastatin-Mediated Inhibition of Translation Initiation.	MTOR
30702500	10.1097/CAD.0000000000000756	Sinensetin induces apoptosis and autophagy in the treatment of human T-cell lymphoma.	MTOR
30688831	10.1097/MPH.0000000000001425	Evaluation of Insulin-mediated Regulation of AKT Signaling in Childhood Acute Lymphoblastic Leukemia.	MTOR
30684308	10.1111/vco.12460	Canine CD4+ T-cell lymphoma identified by flow cytometry exhibits a consistent histomorphology and gene expression profile.	MTOR
30680072	10.18632/oncotarget.26428	Targeted therapies for advanced non-small cell lung cancer.	MTOR
30649751	10.1007/s40264-018-0778-4	Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology.	MTOR
30642353	10.1186/s13045-018-0692-3	Long non-coding RNAs defining major subtypes of B cell precursor acute lymphoblastic leukemia.	MTOR
30594149	10.1186/s12868-018-0482-4	Rapamycin treatment increases hippocampal cell viability in an mTOR-independent manner during exposure to hypoxia mimetic, cobalt chloride.	MTOR
30569126	10.3892/mmr.2018.9737	Ferulic acid ameliorates cerebral infarction by activating Akt/mTOR/4E‑BP1/Bcl‑2 anti‑apoptotic signaling in the penumbral cortex following permanent cerebral ischemia in rats.	MTOR
30564554	10.3389/fonc.2018.00556	Metabolic Reprogramming of Non-Hodgkin's B-Cell Lymphomas and Potential Therapeutic Strategies.	MTOR
30563887	10.1158/0008-5472.CAN-18-1617	Inhibition of Notch Signaling Enhances Chemosensitivity in B-cell Precursor Acute Lymphoblastic Leukemia.	MTOR
30556337	10.1002/jcb.28093	MEG3 affects the progression and chemoresistance of T-cell lymphoblastic lymphoma by suppressing epithelial-mesenchymal transition via the PI3K/mTOR pathway.	MTOR
30549430	10.1111/ajt.15216	Dual blockade of the PI3K/Akt/mTOR pathway inhibits posttransplant Epstein-Barr virus B cell lymphomas and promotes allograft survival.	MTOR
30524948	10.1002/2211-5463.12538	Establishment and characterization of a novel vincristine-resistant diffuse large B-cell lymphoma cell line containing the 8q24 homogeneously staining region.	MTOR
30535452	10.3892/or.2018.6917	Potential efficacy and prognosis of silencing the CRLF2‑mediated AKT/mTOR pathway in pediatric acute B‑cell lymphoblastic leukemia.	MTOR
30528730	10.1016/j.bbrc.2018.12.004	Phosphodiesterase 4B is an effective therapeutic target in colorectal cancer.	MTOR
30518812	10.1038/s41375-018-0305-8	Blood and skin-derived Sezary cells: differences in proliferation-index, activation of PI3K/AKT/mTORC1 pathway and its prognostic relevance.	MTOR
30450663	10.1002/jcb.28038	Activation of the mammalian target of rapamycin signaling pathway underlies a novel inhibitory role of ring finger protein 182 in ventricular remodeling after myocardial ischemia-reperfusion injury.	MTOR
30446641	10.1038/s41467-018-07215-9	Cellular metabolism constrains innate immune responses in early human ontogeny.	MTOR
30431059	10.3892/ijmm.2018.3982	Overexpression of microRNA-183 promotes apoptosis of substantia nigra neurons via the inhibition of OSMR in a mouse model of Parkinson's disease.	MTOR
30413649	10.1158/1535-7163.MCT-18-0478	Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma.	MTOR
30360879	10.1053/j.seminoncol.2018.07.005	New concepts in follicular lymphoma biology: From BCL2 to epigenetic regulators and non-coding RNAs.	MTOR
30359076	10.1152/ajpheart.00487.2018	BMI1 promotes cardiac fibrosis in ischemia-induced heart failure via the PTEN-PI3K/Akt-mTOR signaling pathway.	MTOR
30355676	10.1158/1541-7786.MCR-18-0582	<i>Sleeping Beauty</i> Screen Identifies <i>RREB1</i> and Other Genetic Drivers in Human B-cell Lymphoma.	MTOR
30305939	10.1136/esmoopen-2018-000387	BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance.	MTOR
30297804	10.1038/s41401-018-0161-0	MNK1 inhibitor CGP57380 overcomes mTOR inhibitor-induced activation of eIF4E: the mechanism of synergic killing of human T-ALL cells.	MTOR
30279524	10.1038/s41598-018-32965-3	Microgravity induces autophagy via mitochondrial dysfunction in human Hodgkin's lymphoma cells.	MTOR
30269036	10.1016/j.leukres.2018.09.009	Expression of the miR-150 tumor suppressor is restored by and synergizes with rapamycin in a human leukemia T-cell line.	MTOR
30257881	10.1182/blood-2018-05-848515	UCH-L1 bypasses mTOR to promote protein biosynthesis and is required for MYC-driven lymphomagenesis in mice.	MTOR
30249539	10.1016/j.jbior.2018.09.012	IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia: An update.	MTOR
30244168	10.1016/j.cellsig.2018.09.012	BAFF inhibits autophagy promoting cell proliferation and survival by activating Ca<sup>2+</sup>-CaMKII-dependent Akt/mTOR signaling pathway in normal and neoplastic B-lymphoid cells.	MTOR
30231317	10.1200/EDBK_200829	Treatment of Primary Central Nervous System Lymphoma: From Chemotherapy to Small Molecules.	MTOR
30224339	10.1158/1078-0432.CCR-18-0867	NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263.	MTOR
30221690	10.3892/ijmm.2018.3868	Astragalus polysaccharide combined with 10-hydroxycamptothecin inhibits metastasis in non-small cell lung carcinoma cell lines via the MAP4K3/mTOR signaling pathway.	MTOR
30216478	10.1002/hon.2561	The role of maintenance therapy in patients with diffuse large B cell lymphoma: A systematic review and meta-analysis.	MTOR
30198569	10.1111/bjh.15591	The miR-17~92 cluster activates mTORC1 in mantle cell lymphoma by targeting multiple regulators in the STK11/AMPK/TSC/mTOR pathway.	MTOR
30198340	10.1080/21691401.2018.1478844	Rituximab (anti-CD20)-modified AZD-2014-encapsulated nanoparticles killing of B lymphoma cells.	MTOR
30196309	10.12659/MSM.909726	Marsdenia Tenacissima Extract Inhibits Proliferation and Promotes Apoptosis in Human Ovarian Cancer Cells.	MTOR
30193222	10.1016/j.envpol.2018.08.070	Atrazine hinders PMA-induced neutrophil extracellular traps in carp via the promotion of apoptosis and inhibition of ROS burst, autophagy and glycolysis.	MTOR
30156609	10.1590/1414-431X20186839	Knockdown of long non-coding RNA ANRIL inhibits tumorigenesis in human gastric cancer cells via microRNA-99a-mediated down-regulation of BMI1.	MTOR
30147333	10.2147/OTT.S142264	Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date.	MTOR
30123222	10.3389/fimmu.2018.01799	Activating Autophagy Enhanced the Antitumor Effect of Antibody Drug Conjugates Rituximab-Monomethyl Auristatin E.	MTOR
30116377	10.3892/etm.2018.6345	Curcumin inhibits proliferation and promotes apoptosis of breast cancer cells.	MTOR
30104685	10.1038/s41598-018-30509-3	Drug-based perturbation screen uncovers synergistic drug combinations in Burkitt lymphoma.	MTOR
30067771	10.1371/journal.pone.0200725	The phosphoinositide-3 kinase (PI3K)-δ,γ inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies.	MTOR
30066877	10.3892/mmr.2018.9321	UNBS5162 inhibits proliferation of human melanoma cells by inducing apoptosis via the PI3K/Akt pathway.	MTOR
30049438	10.1016/j.bbrc.2018.07.019	ZKSCAN3 promotes breast cancer cell proliferation, migration and invasion.	MTOR
30025915	10.1016/j.mce.2018.07.007	Metformin suppresses growth and adrenocorticotrophic hormone secretion in mouse pituitary corticotroph tumor AtT20 cells.	MTOR
30025393	10.1159/000491899	Function of SLC7A7 in T-Cell Acute Lymphoblastic Leukemia.	MTOR
30021906	10.1128/JVI.01138-18	Kaposi's Sarcoma-Associated Herpesvirus Latency Locus Renders B Cells Hyperresponsive to Secondary Infections.	MTOR
30002430	10.1038/s41598-018-28619-z	Angelica gigas Nakai and Decursin Downregulate Myc Expression to Promote Cell Death in B-cell Lymphoma.	MTOR
29987212	10.3390/ijms19071997	Senescence Induces Dysfunctions in Endothelial Progenitor Cells and Osteoblasts by Interfering Translational Machinery and Bioenergetic Homeostasis.	MTOR
29961897	10.1093/abbs/gmy070	Targeting the PI3K/Akt/mTOR signaling pathway by pterostilbene attenuates mantle cell lymphoma progression.	MTOR
29956761	10.3892/mmr.2018.9220	Aclidinium bromide inhibits the growth and metastasis of gastric cancer MKN‑28 cells via the PI3K signaling pathway.	MTOR
29951132	10.1186/s13148-018-0516-x	Acute leukemia cells resistant to PI3K/mTOR inhibition display upregulation of P2RY14 expression.	MTOR
29950218	10.7534/j.issn.1009-2137.2018.03.023	[Effects of Silencing NSD2 Gene by shRNA on Proliferation, Apoptosis and Akt /mTOR Signal Pathway in OCI-Ly3 Cells].	MTOR
29950132	10.1080/15548627.2018.1466013	Role of the MAPK/cJun NH<sub>2</sub>-terminal kinase signaling pathway in starvation-induced autophagy.	MTOR
29949919	10.3390/ijms19071878	Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update.	MTOR
29946778	10.1007/978-3-319-77736-8_7	Non-Hodgkin Lymphoma Metabolism.	MTOR
29937999	10.18632/oncotarget.25463	Target amplicon exome-sequencing identifies promising diagnosis and prognostic markers involved in RTK-RAS and PI3K-AKT signaling as central oncopathways in primary central nervous system lymphoma.	MTOR
29932870	10.1096/fj.201701386	ERα36 gene silencing promotes tau protein phosphorylation, inhibits cell proliferation, and induces apoptosis in human neuroblastoma SH-SY5Y cells.	MTOR
29925955	10.1038/s41586-018-0290-0	A multiprotein supercomplex controlling oncogenic signalling in lymphoma.	MTOR
29916537	10.3892/mmr.2018.9180	Liraglutide improves cognitive impairment via the AMPK and PI3K/Akt signaling pathways in type 2 diabetic rats.	MTOR
29907126	10.1186/s13045-018-0621-5	NF-κB signaling and its relevance to the treatment of mantle cell lymphoma.	MTOR
29802156	10.1042/BSR20171691	Curcumin improves age-related and surgically induced osteoarthritis by promoting autophagy in mice.	MTOR
29774169	10.1186/s40164-018-0103-z	Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma.	MTOR
29774105	10.18632/oncotarget.25072	Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma.	MTOR
29769264	10.1182/blood-2017-11-818617	RhoA G17V is sufficient to induce autoimmunity and promotes T-cell lymphomagenesis in mice.	MTOR
29765528	10.18632/oncotarget.24989	Metabolic changes associated with metformin potentiates Bcl-2 inhibitor, Venetoclax, and CDK9 inhibitor, BAY1143572 and reduces viability of lymphoma cells.	MTOR
29750888	10.33549/physiolres.933738	Adiponectin enhances biological functions of vascular endothelial progenitor cells through the mTOR-STAT3 signaling pathway.	MTOR
29734016	10.1016/j.neo.2018.03.002	Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma.	MTOR
29731854	10.3892/ol.2018.8141	Cantharidin suppresses cell growth and migration, and activates autophagy in human non-small cell lung cancer cells.	MTOR
29719377	10.2147/DDDT.S160557	Attenuation of everolimus-induced cytotoxicity by a protective autophagic pathway involving ERK activation in renal cell carcinoma cells.	MTOR
29716528	10.1186/s12885-018-4391-9	PEST-containing nuclear protein mediates the proliferation, migration, and invasion of human neuroblastoma cells through MAPK and PI3K/AKT/mTOR signaling pathways.	MTOR
29710456	10.1016/j.biopha.2018.01.067	Vitexin reverses the autophagy dysfunction to attenuate MCAO-induced cerebral ischemic stroke via mTOR/Ulk1 pathway.	MTOR
29668543	10.1097/MPH.0000000000001179	Multiple Epstein-Barr Virus-associated Smooth Muscle Sarcomas of the Gut in a Child Treated for Acute Lymphoblastic Leukemia.	MTOR
29667769	10.1002/jcp.26539	Targeting the phosphatidylinositol 3-kinase/Akt/mechanistic target of rapamycin signaling pathway in B-lineage acute lymphoblastic leukemia: An update.	MTOR
29666061	10.1158/0008-5472.CAN-17-3107	Deptor Is a Novel Target of Wnt/β-Catenin/c-Myc and Contributes to Colorectal Cancer Cell Growth.	MTOR
29658590	10.3892/or.2018.6361	Cucurbitacin D impedes gastric cancer cell survival via activation of the iNOS/NO and inhibition of the Akt signalling pathway.	MTOR
29620191	10.3892/ijo.2018.4357	Arsenic disulfide‑induced apoptosis and its potential mechanism in two‑ and three‑dimensionally cultured human breast cancer MCF‑7 cells.	MTOR
29616118	10.3892/ol.2018.8089	Adenosine induces intrinsic apoptosis via the PI3K/Akt/mTOR signaling pathway in human pharyngeal squamous carcinoma FaDu cells.	MTOR
29603593	10.1002/pbc.27062	Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia.	MTOR
29578162	10.4103/0973-1482.172111	The autophagy induced by curcumin via MEK/ERK pathway plays an early anti-leukemia role in human Philadelphia chromosome-positive acute lymphoblastic leukemia SUP-B15 cells.	MTOR
29574283	10.1016/j.biopha.2018.03.009	VS-5584 as a PI3K/mTOR inhibitor enhances apoptotic effects of subtoxic dose arsenic trioxide via inhibition of NF-κB activity in B cell precursor-acute lymphoblastic leukemia.	MTOR
29570671	10.3390/ijms19040966	St. John's Wort Regulates Proliferation and Apoptosis in MCF-7 Human Breast Cancer Cells by Inhibiting AMPK/mTOR and Activating the Mitochondrial Pathway.	MTOR
29569971	10.1080/10428194.2018.1452213	Src family kinase inhibitor bosutinib enhances retinoic acid-induced differentiation of HL-60 leukemia cells.	MTOR
29568883	10.3892/mmr.2018.8769	Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway.	MTOR
29556265	10.3892/etm.2018.5875	Advanced oxidation protein products inhibit the autophagy of renal tubular epithelial cells.	MTOR
29552123	10.3892/ol.2018.7971	Expression profiling analysis of autophagy-related genes in perineural invasion of cutaneous squamous cell carcinoma.	MTOR
29550382	10.1016/S2352-3026(18)30030-9	Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial.	MTOR
29545863	10.3892/etm.2018.5830	Triptolide induces autophagy and apoptosis through ERK activation in human breast cancer MCF-7 cells.	MTOR
29515122	10.1038/s41419-018-0413-4	Pan-class I  PI3-kinase inhibitor BKM120 induces MEK1/2-dependent mitotic catastrophe in non-Hodgkin lymphoma leading to apoptosis or polyploidy determined by Bax/Bak and p53.	MTOR
29505032	10.1038/nm.4505	Single-cell developmental classification of B cell precursor acute lymphoblastic leukemia at diagnosis reveals predictors of relapse.	MTOR
29504068	10.1007/s10637-017-0552-y	Histone deacetylase inhibitor chidamide induces growth inhibition and apoptosis in NK/T lymphoma cells through ATM-Chk2-p53-p21 signalling pathway.	MTOR
29485914	10.1089/dna.2017.3874	Streptozotocin-Induced Autophagy Reduces Intracellular Insulin in Insulinoma INS-1E Cells.	MTOR
29483777	10.2147/OTT.S149788	Antitumor effect of triptolide in T-cell lymphoblastic lymphoma by inhibiting cell viability, invasion, and epithelial-mesenchymal transition via regulating the PI3K/AKT/mTOR pathway.	MTOR
29483509	10.1038/s41467-018-03028-y	Fatty Acid Synthase induced S6Kinase facilitates USP11-eIF4B complex formation for sustained oncogenic translation in DLBCL.	MTOR
29463831	10.1038/s41598-018-21570-z	Shikonin exerts antitumor activity in Burkitt's lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin.	MTOR
29456744	10.3892/ol.2018.7743	Cardamonin enhances the anti-proliferative effect of cisplatin on ovarian cancer.	MTOR
29399633	10.1126/sciadv.aar5701	Discrete roles and bifurcation of PTEN signaling and mTORC1-mediated anabolic metabolism underlie IL-7-driven B lymphopoiesis.	MTOR
29399197	10.3892/ol.2017.7451	Licochalcone A inhibits PI3K/Akt/mTOR signaling pathway activation and promotes autophagy in breast cancer cells.	MTOR
29387218	10.3892/ol.2017.7341	<i>Celastrus orbiculatus</i> extracts induce apoptosis and inhibit invasion by targeting the maspin gene in human gastric adenocarcinoma cells.	MTOR
29387064	10.3389/fimmu.2017.02005	Epstein-Barr Virus Susceptibility in Activated PI3Kδ Syndrome (APDS) Immunodeficiency.	MTOR
29386059	10.1186/s13046-017-0639-5	MicroRNA-150 enhances radiosensitivity by inhibiting the AKT pathway in NK/T cell lymphoma.	MTOR
29384404	10.1080/10428194.2018.1427855	A novel fusion of PDGFRB to TSC1, an intrinsic suppressor of mTOR-signaling pathway, in a chronic eosinophilic leukemia patient with t(5;9)(q32;q34).	MTOR
29383700	10.1111/bjh.15079	Venetoclax as a single agent and in combination with PI3K-MTOR1/2 kinase inhibitors against ibrutinib sensitive and resistant mantle cell lymphoma.	MTOR
29383130	10.18632/oncotarget.22414	GSK-3β inhibitor, 9-ING-41, reduces cell viability and halts proliferation of B-cell lymphoma cell lines as a single agent and in combination with novel agents.	MTOR
29370086	10.3390/cancers10020031	Cell-Penetrating CaCO₃ Nanocrystals for Improved Transport of NVP-BEZ235 across Membrane Barrier in T-Cell Lymphoma.	MTOR
29361117	10.1093/jnen/nlx121	Discrepancy Between Low Levels of mTOR Activity and High Levels of P-S6 in Primary Central Nervous System Lymphoma May Be Explained by PAS Domain-Containing Serine/Threonine-Protein Kinase-Mediated Phosphorylation.	MTOR
29360358	10.1021/acs.jmedchem.7b01465	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.	MTOR
29355544	10.1016/j.lfs.2018.01.014	Quercetin suppresses breast cancer stem cells (CD44<sup>+</sup>/CD24<sup>-</sup>) by inhibiting the PI3K/Akt/mTOR-signaling pathway.	MTOR
29344647	10.3892/ijmm.2018.3393	Autophagy regulates the degeneration of the auditory cortex through the AMPK-mTOR-ULK1 signaling pathway.	MTOR
29322846	10.1080/10428194.2017.1421760	PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise.	MTOR
29311820	10.3389/fnmol.2017.00432	Activation of Autophagy Contributes to Sevoflurane-Induced Neurotoxicity in Fetal Rats.	MTOR
29262896	10.7534/j.issn.1009-2137.2017.06.017	[Effects of Sinomenine on Proliferation and Apoptosis of MCL Jeko-1 Cell Line and Its Mechanism].	MTOR
29247643	10.1016/j.cbi.2017.12.017	Traditional herbal medicine-derived sulforaphene promotes mitophagic cell death in lymphoma cells through CRM1-mediated p62/SQSTM1 accumulation and AMPK activation.	MTOR
29234922	10.1007/s00280-017-3499-y	Pharmacokinetically-targeted dosed everolimus maintenance therapy in lymphoma patients.	MTOR
29234489	10.18632/genesandcancer.154	Molecular insights: Suppression of EGFR and AKT activation by a small molecule in non-small cell lung cancer.	MTOR
29228628	10.18632/oncotarget.22178	Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling.	MTOR
29207056	10.3892/ijmm.2017.3285	Different roles of Akt and mechanistic target of rapamycin in serum‑dependent chondroprotection of human osteoarthritic chondrocytes.	MTOR
29185784	10.1089/dna.2017.3922	miR-21 Inhibitors Modulate Biological Functions of Gastric Cancer Cells via PTEN/PI3K/mTOR Pathway.	MTOR
29172833	10.1080/0284186X.2017.1404634	A systematic review of targeted agents for non-small cell lung cancer.	MTOR
29157834	10.1016/j.phymed.2017.09.021	16-Hydroxycleroda-3, 13-dien-15, 16-olide inhibits the proliferation and induces mitochondrial-dependent apoptosis through Akt, mTOR, and MEK-ERK pathways in human renal carcinoma cells.	MTOR
29156828	10.18632/oncotarget.21411	The β-glucan from <i>Lentinus edodes</i> suppresses cell proliferation and promotes apoptosis in estrogen receptor positive breast cancers.	MTOR
29115429	10.3892/mmr.2017.7868	Resveratrol-mediated apoptosis in renal cell carcinoma via the p53/AMP‑activated protein kinase/mammalian target of rapamycin autophagy signaling pathway.	MTOR
29115419	10.3892/mmr.2017.7840	Effect of β‑ecdysterone on glucocorticoid‑induced apoptosis and autophagy in osteoblasts.	MTOR
29113237	10.3892/ol.2017.6930	MicroRNA-10a suppresses breast cancer progression via PI3K/Akt/mTOR pathway.	MTOR
29093603	10.1055/s-0043-118907	PI3K/AKT/mTOR Pathway in Ovarian Cancer Treatment: Are We on the Right Track?	MTOR
29077243	10.1111/cas.13431	Dual inhibition of the mTORC1 and mTORC2 signaling pathways is a promising therapeutic target for adult T-cell leukemia.	MTOR
29076004	10.1007/s10238-017-0478-x	High mTOR expression independently prognosticates poor clinical outcome to induction chemotherapy in acute lymphoblastic leukemia.	MTOR
29070114	10.7534/j.issn.1009-2137.2017.05.020	[Effects of mTOR Inhibitor Rapamycin on Burkitt's Lymphoma Cells].	MTOR
29066507	10.1158/1078-0432.CCR-17-1041	PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy.	MTOR
29061796	10.21873/anticanres.12064	Differential Anticancer Activity of Pterostilbene Against Three Subtypes of Human Breast Cancer Cells.	MTOR
29050265	10.18632/oncotarget.19592	Reactive oxygen species dependent phosphorylation of the liver kinase B1/AMP activated protein kinase/ acetyl-CoA carboxylase signaling is critically involved in apoptotic effect of lambertianic acid in hepatocellular carcinoma cells.	MTOR
29046392	10.1042/BCJ20170386	Nutlin-3 plus tanshinone IIA exhibits synergetic anti-leukemia effect with imatinib by reactivating p53 and inhibiting the AKT/mTOR pathway in Ph+ ALL.	MTOR
28964970	10.1016/j.cellsig.2017.09.020	Metformin triggers apoptosis in PEL cells and alters bortezomib-induced Unfolded Protein Response increasing its cytotoxicity and inhibiting KSHV lytic cycle activation.	MTOR
28952842	10.1080/10428194.2017.1379077	Clinical significance of chemokine receptor CXCR4 and mammalian target of rapamycin (mTOR) expression in patients with diffuse large B-cell lymphoma.	MTOR
28927098	10.3892/ol.2017.6587	Notch 1 is a valuable therapeutic target against cell survival and proliferation in clear cell renal cell carcinoma.	MTOR
28905990	10.1002/ijc.31044	The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.	MTOR
28864640	10.1158/2159-8290.CD-17-0714	Spotlight on Ibrutinib in PCNSL: Adding Another Feather to Its Cap.	MTOR
28860565	10.1038/s41598-017-10684-5	Interleukin-6-dependent growth in a newly established plasmablastic lymphoma cell line and its therapeutic targets.	MTOR
32300390	10.14740/jh320w	Rituximab-Based Therapy in Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients: Individualized Risk-Adapted Therapy Approach Using Molecular Subtypes.	MTOR
28854163	10.12659/msm.906389	Decreasing Eukaryotic Initiation Factor 3C (EIF3C) Suppresses Proliferation and Stimulates Apoptosis in Breast Cancer Cell Lines Through Mammalian Target of Rapamycin (mTOR) Pathway.	MTOR
28845578	10.1111/1759-7714.12496	Patient harboring a novel PIK3CA point mutation after acquired resistance to crizotinib in an adenocarcinoma with ROS1 rearrangement: A case report and literature review.	MTOR
28829592	10.1021/acs.jmedchem.7b00930	5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.	MTOR
28731147	10.3892/mmr.2017.7064	Beclin 1 overexpression inhibits chondrocyte apoptosis and downregulates extracellular matrix metabolism in osteoarthritis.	MTOR
28724379	10.1186/s12967-017-1258-9	Regulation of glucose uptake in lymphoma cell lines by c-MYC- and PI3K-dependent signaling pathways and impact of glycolytic pathways on cell viability.	MTOR
28713965	10.3892/mmr.2017.6989	Dihydroartemisinin and gefitinib synergistically inhibit NSCLC cell growth and promote apoptosis via the Akt/mTOR/STAT3 pathway.	MTOR
28703366	10.1002/ptr.5866	Synergistic Effect of TPD7 and Berberine against Leukemia Jurkat Cell Growth through Regulating Ephrin-B2 Signaling.	MTOR
33531656	10.1038/s41375-021-01132-5	Dual targeting of MTOR as a novel therapeutic approach for high-risk B-cell acute lymphoblastic leukemia.	MTOR
32206779	10.1182/blood.2019002792	Increased mTOR activation in idiopathic multicentric Castleman disease.	MTOR
29076004	10.1007/s10238-017-0478-x	High mTOR expression independently prognosticates poor clinical outcome to induction chemotherapy in acute lymphoblastic leukemia.	MTOR
28159681	10.1016/j.canlet.2017.01.035	The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL).	MTOR
28151717	10.1158/1078-0432.CCR-15-2869	Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.	MTOR
27939840	10.1016/j.antiviral.2016.12.002	Niclosamide inhibits lytic replication of Epstein-Barr virus by disrupting mTOR activation.	MTOR
27018341	10.1002/jcb.25559	Targeting the mTOR Pathway in Leukemia.	MTOR
26722032		Torin2 Potentiates Anticancer Effects on Adult T-Cell Leukemia/Lymphoma by Inhibiting Mammalian Target of Rapamycin.	MTOR
25849580	10.1186/s12964-015-0091-0	Distinct inhibitory effects on mTOR signaling by ethanol and INK128 in diffuse large B-cell lymphoma.	MTOR
25747970	10.3109/10428194.2015.1026816	Catalytic mammalian target of rapamycin inhibitors as antineoplastic agents.	MTOR
25208880	10.1158/1078-0432.CCR-13-3172	mTOR inhibitors induce cell-cycle arrest and inhibit tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells.	MTOR
23693095	10.1186/1471-2407-13-250	Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease--a combined tissue microarray, in vitro and in vivo study.	MTOR
23573198	10.1371/journal.pone.0059335	Mammalian target of rapamycin (mTOR) activity dependent phospho-protein expression in childhood acute lymphoblastic leukemia (ALL).	MTOR
22902049	10.1016/j.leukres.2012.07.016	Activation of mammalian target of rapamycin in diffuse large B-cell lymphoma: a clinicopathological study.	MTOR
22899290	10.1038/modpathol.2012.141	Activity and complexes of mTOR in diffuse large B-cell lymphomas--a tissue microarray study.	MTOR
21973240	10.3109/10428194.2011.628062	Association of genetic variations in mTOR with risk of childhood acute lymphoblastic leukemia in a Chinese population.	MTOR
21943204	10.1111/j.1600-0714.2011.01083.x	High mTOR expression is associated with a worse oncological outcome in laryngeal carcinoma treated with postoperative radiotherapy: a pilot study.	MTOR
21277936	10.1016/j.exphem.2011.01.005	Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors.	MTOR
20960030	10.1007/s10637-010-9558-4	Schedule-dependent inhibition of T-cell lymphoma cells by cotreatment with the mTOR inhibitor everolimus and anticancer drugs.	MTOR
19608873	10.2353/ajpath.2009.080451	Activation of mTORC1 signaling pathway in AIDS-related lymphomas.	MTOR
19373664	10.1080/10428190802709446	mTOR inhibition and adult T-cell leukemia.	MTOR
19293424	10.1182/blood-2008-11-191783	Alcohol consumption and decreased risk of non-Hodgkin lymphoma: role of mTOR dysfunction.	MTOR
17148679	10.2353/ajpath.2006.051078	Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.	MTOR
16141350	10.1182/blood-2005-06-2208	Proangiogenic stimulation of bone marrow endothelium engages mTOR and is inhibited by simultaneous blockade of mTOR and NF-kappaB.	MTOR
35248829	10.1016/j.redox.2022.102268	mTOR inhibition downregulates glucose-6-phosphate dehydrogenase and induces ROS-dependent death in T-cell acute lymphoblastic leukemia cells.	MTOR
33821934	10.1093/abbs/gmab031	Anti-DLBCL efficacy of DCZ0825 in vitro and in vivo: involvement of the PI3K‒AKT‒mTOR/JNK pathway.	MTOR
33191863	10.1080/16078454.2020.1845501	Blockade of PLD1 potentiates the antitumor effects of bortezomib in multiple myeloma cells by inhibiting the mTOR/NF-κB signal pathway.	MTOR
33055173	10.1158/1078-0432.CCR-20-1215	Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma.	MTOR
32098126	10.3390/molecules25040971	Benzoxazole Derivative K313 Induces Cell Cycle Arrest, Apoptosis and Autophagy Blockage and Suppresses mTOR/p70S6K Pathway in Nalm-6 and Daudi Cells.	MTOR
30808136	10.13201/j.issn.1001-1781.2019.02.008	[Expression of mTOR and 4E-BP1 in extranodal Nasal-type NK/T-cell Lymphoma and implication for prognosis].	MTOR
29667769	10.1002/jcp.26539	Targeting the phosphatidylinositol 3-kinase/Akt/mechanistic target of rapamycin signaling pathway in B-lineage acute lymphoblastic leukemia: An update.	MTOR
28952842	10.1080/10428194.2017.1379077	Clinical significance of chemokine receptor CXCR4 and mammalian target of rapamycin (mTOR) expression in patients with diffuse large B-cell lymphoma.	MTOR
28854163	10.12659/msm.906389	Decreasing Eukaryotic Initiation Factor 3C (EIF3C) Suppresses Proliferation and Stimulates Apoptosis in Breast Cancer Cell Lines Through Mammalian Target of Rapamycin (mTOR) Pathway.	MTOR
28082737	10.1038/leu.2017.13	Phosphoproteomic analysis reveals hyperactivation of mTOR/STAT3 and LCK/Calcineurin axes in pediatric early T-cell precursor ALL.	MTOR
27693556	10.1016/j.canlet.2016.09.016	Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.	MTOR
27756877	10.18632/oncotarget.12654	Marsdenia tenacissimae extraction (MTE) inhibits the proliferation and induces the apoptosis of human acute T cell leukemia cells through inactivating PI3K/AKT/mTOR signaling pathway via PTEN enhancement.	MTOR
27473087	10.1007/s13277-016-5272-y	Growth inhibitory effect of rapamycin in Hodgkin-lymphoma cell lines characterized by constitutive NOTCH1 activation.	MTOR
27235137	10.1182/blood-2016-02-700328	Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia.	MTOR
26892465	10.1186/s13045-016-0241-x	Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia.	MTOR
26549638	10.3892/ijo.2015.3231	PF-04691502, a dual PI3K/mTOR inhibitor has potent pre-clinical activity by inducing apoptosis and G1 cell cycle arrest in aggressive B-cell non-Hodgkin lymphomas.	MTOR
25729885	10.1080/15384047.2015.1019184	Small molecule schweinfurthins selectively inhibit cancer cell proliferation and mTOR/AKT signaling by interfering with trans-Golgi-network trafficking.	MTOR
25228590	10.18632/oncotarget.2372	Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.	MTOR
24970801	10.18632/oncotarget.2071	Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma.	MTOR
24112608	10.1186/1471-2407-13-471	Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma.	MTOR
23963361	10.1158/1535-7163.MCT-13-0239	Novel treatment for mantle cell lymphoma including therapy-resistant tumor by NF-κB and mTOR dual-targeting approach.	MTOR
22895079	10.4161/cbt.21460	Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.	MTOR
21926965	10.1038/leu.2011.248	Involvement of the Syk-mTOR pathway in follicular lymphoma cell invasion and angiogenesis.	MTOR
21631271	10.5858/2009-0691-OA.1	Uniform expression of Notch1, suppressor of B-cell-specific gene expression, in plasmablastic lymphoma.	MTOR
19757306	10.3109/10428190903207548	Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies.	MTOR
19489223		[Activation and clinicopathologic significance of AKT/mTOR signaling pathway in diffuse large B-cell lymphoma].	MTOR
18596736	10.1038/leu.2008.178	Interleukin-4 stimulates proliferation and growth of T-cell acute lymphoblastic leukemia cells by activating mTOR signaling.	MTOR
17363738	10.1182/blood-2006-08-039883	Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia.	MTOR
17110454	10.1182/blood-2006-08-042192	mTOR-dependent synthesis of Bcl-3 controls the retraction of fibrin clots by activated human platelets.	MTOR
32749680	10.1002/jcp.29943	Light-emitting diode irradiation induces AKT/mTOR-mediated apoptosis in human pancreatic cancer cells and xenograft mouse model.	MTOR
29185784	10.1089/dna.2017.3922	miR-21 Inhibitors Modulate Biological Functions of Gastric Cancer Cells via PTEN/PI3K/mTOR Pathway.	MTOR
28192480	10.1371/journal.pone.0170771	mTOR activity in AIDS-related diffuse large B-cell lymphoma.	MTOR
27267853	10.1158/1078-0432.CCR-16-0609	Recurrent Mutations in the MTOR Regulator RRAGC in Follicular Lymphoma.	MTOR
27147575	10.18632/oncotarget.9061	Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells.	MTOR
25215588	10.3390/molecules190914304	Inhibition of the PI3K/Akt/mTOR signaling pathway in diffuse large B-cell lymphoma: current knowledge and clinical significance.	MTOR
22473959	10.1084/jem.20111470	Vital roles of mTOR complex 2 in Notch-driven thymocyte differentiation and leukemia.	MTOR
21861134	10.1007/s00432-011-1037-6	Down-regulation of JAK1 by RNA interference inhibits growth of the lung cancer cell line A549 and interferes with the PI3K/mTOR pathway.	MTOR
21334199	10.1016/j.ejca.2011.01.003	Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001.	MTOR
19225536	10.1038/leu.2008.348	Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma.	MTOR
19176054		[Study on activation of AKT/mTOR pathway in anaplastic large cell lymphoma].	MTOR
18339899	10.1182/blood-2007-07-103481	Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma.	MTOR
35191952	10.1158/1541-7786.MCR-21-0729	PARK2 regulates eIF4B-driven lymphomagenesis.	MTOR
35105670	10.1158/1541-7786.MCR-21-0729	PARK2 regulates eIF4B-driven lymphomagenesis.	MTOR
7822316	10.1074/jbc.270.2.815	Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells.	MTOR
30720463	10.1172/JCI98288	Follicular lymphoma-associated mutations in vacuolar ATPase ATP6V1B2 activate autophagic flux and mTOR.	MTOR
22094587	10.1038/leu.2011.322	Silencing of ETV6/RUNX1 abrogates PI3K/AKT/mTOR signaling and impairs reconstitution of leukemia in xenografts.	MTOR
20354178	10.1158/0008-5472.CAN-09-4072	The antidepressant sertraline inhibits translation initiation by curtailing mammalian target of rapamycin signaling.	MTOR
19321861	10.1182/blood-2008-09-179762	A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase-regulated mammalian target of rapamycin activation.	MTOR
18769147	10.4161/cc.7.18.6733	GSK-3beta inhibition: at the crossroad between Akt and mTOR constitutive activation to enhance cyclin D1 protein stability in mantle cell lymphoma.	MTOR
26362858	10.1007/s12185-015-1858-1	Rapamycin restores p14, p15 and p57 expression and inhibits the mTOR/p70S6K pathway in acute lymphoblastic leukemia cells.	MTOR
26043155	10.1080/15548627.2015.1055439	TNFAIP3 promotes survival of CD4 T cells by restricting MTOR and promoting autophagy.	MTOR
25915427	10.18632/oncotarget.3802	MicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma.	MTOR
25909227	10.18632/oncotarget.3729	MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.	MTOR
26917778	10.1182/blood-2015-02-629485	4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells.	MTOR
25124033	10.1074/jbc.M114.575571	Degradation of Tiam1 by casein kinase 1 and the SCFβTrCP ubiquitin ligase controls the duration of mTOR-S6K signaling.	MTOR
18704194	10.1172/JCI33337	Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells.	MTOR
